Purpose: The aim of this study is to evaluate survival and prognostic factors in patients with brain metastases (BM) who received whole brain radiotherapy (WBRT). Methods and Methods: Patients (118) were retrospectively identified through the hospital data-base, patients' charts and imaging studies. results: Cancer breast was the most common primary site (38) followed by the lung (24). The median survival for all patients was 4 months. Higher Karnofsky score (p = 0.04), single metastases (p = 0.04) and systemic chemotherapy (p = 0.01) are associated with better survival. The recursive partitioning analysis showed strong relation with survival (p < 0.01). Different radiotherapy doses and fractionation schedules did not altered survival. conclusion: WBRT is an effective treatment in the management of BM. Multimodality treatments including surgery, radiosurgery and chemotherapy with WBRT should be used to improve survival mainly in those patients with single metastases, higher KPS and controlled extra cranial disease.
Original article

IntroductIon
Brain metastases (BM) are an important cause of morbidity and mortality and, occurring in approximately 10% to 30% of adult cancer patients. The risk of developing brain metastases varies according to primary tumor. The most common primary sites are the lung followed by the breast 1 . Whole brain radiotherapy (WBRT) and corticosteroid are the standard treatment to patients with brain metastases 2, 3 . The use of adjuvant WBRT after resection or radiosurgery has been proven to be effective in terms of improving local control of brain metastases and thus, the likelihood of neurological death is decreased 4 . For most patients who present with multiple brain metastases, the goal of treatment is palliation. Specifically, the main expectations of therapy are an improvement in presenting neurological symptoms and prevention of neurological deterioration 5 .
The prognosis of patients with brain metastases is poor; the median survival time of untreated patients is approximately 1 month. With WBRT, the overall median survival time after diagnosis is approximately 4 months 6 . Radiation Therapy Oncology Group (RTOG) showed that as many as 40% of high-risk patients do not survive more than 2 months. RTOG classified patients into three classes Table (1) based on recursive partitioning analysis (RPA) 7 . It provided a tool to identify the prognosis and patients who may not benefit from WBRT.
There is no consensus on the optimal radiation schedule for patients with brain metastases. Standard treatment regimen include all dose ranges which evaluated in the early RTOG studies and is dependent upon issues such as the severity of CNS symptoms, the extent of systemic disease and physician preference 8 . The aim of this study is to evaluate survival and prognostic factors in patients with BM who received WBRT.
PAtIEntS And MEtHodS
Patients, record were retrospectively identified through the hospital data-base, patients' charts and imaging studies. WBRT was performed in all patients with BM using 6 MV photons of a linear accelerator. The whole brain was irradiated by usual bilateral fields that encompassed the cranium with a 1 cm margin. Regarding radiation dose, patients were heterogeneously treated according to the physician's decision. During the study period three fractionation schemes were used: hypofractionation with daily fractions of 3 Gy, five days per week to a planned total dose of 30 Gy (n = 95), hypofractionation with daily fractions of 4 Gy, five days per week to a planned total dose of 20 Gy (n = 14) and conventional fractionation with daily fractions of 2 Gray (Gy), five days per week to a planned total dose of 40 Gy (n = 9). Boost dose was given in cases of single brain metastasis with different fractionation schemes. No surgical resection was done. Systemic chemotherapy administered to the patients (n=28) with active systemic disease after WBRT. The supportive care (corticosteroid therapy) was introduced in the beginning of treatment and during radiotherapy.
Statistical design:
This was a retrospective study and bias can not be excluded. There was a difficulty to determine the accurate date of death because there is no available mortality registration. We contact with the family of patients to know the mortality date. The endpoint of the study was overall survival. Survival was calculated from the first day of radiotherapy using the method of Kaplan Meier. Survival curves were compared using the log-rank test. The covariates examined in all cases were: age, sex, primary tumor type, extent of disease, initial Karnofsky score, dose and fractionation radiotherapy schedule and recursive partitioning analysis (RPA) class. All factors with a P-value ≤ 0.05 were significant.
rESuLtS
During the period of 2006 to 2009, 118 patients with brain metastases, who were treated with WBRT at our institution in the department of radiation Oncology, University of Assiut. Brain metastases were detected by contrast-enhanced cerebral computed tomography and/or magnetic resonance imaging. Age of patients ranged from 17-82 years (Median = 47 years). Sixty one patients were female and fifty seven patients were male. Cancer breast was the most common primary site (n = 38) followed by the lung (n = 24) Table (2 
dISScuSIon
Brain metastases are the most common intra-cranial tumor accounting significantly more than one-half of brain tumors in adults. WBRT is essential for most cases of multiple BM. The benefit with the use of WBRT over supportive care alone, in terms of symptom control, quality of life, or survival remains unclear, particularly in patients with poor performance status and/or active extracranial disease 8 . The goal of postoperative WBRT in patients with solitary BM is to destroy microscopic residual cancer cells at the site of resection and others localizations within the brain. Two of the three randomized trials (WBRT versus surgery plus WBRT) reported a statistically significant improvement in overall median survival for surgery plus WBRT 9, 10, 11 . This improvement demonstrated in patients with good performance status and absence of extracranial disease (RPA class I). In our trial, no patient performed surgery or sterotactic radiotherapy but conventional boost dose was given in cases of single BM. A larger trial (RTOG 95-08) 12 provides compelling evidence for the use of stereotactic radiosurgery (SRS) boost following WBRT in patients with newly diagnosed one to three BM. In our study, patients with multiple brain metastases had poorer survival than patients with single brain metastases (P = 0.04). We should encourage our patients for referral to receive SRS.
Most of our patients received a common standard dosefractionation schedule (3000 cGy in 10 fractions), however, there is no difference in survival compared with other dosefractionation schedules (P=0.2). RTOG attempted several randomized controlled trials 13, 14, 15 to evaluate the use of altered dose-fractionation schedules. However, there was no benefit in terms of overall survival or neurologic function improvement with altered dose-fractionation schedules as compared to a standard dose-fractionation schedule (3000 cGy in 10 fractions). None of the negative trials commented on confidence intervals or power calculations. As 2000 cGy in 5 fractions is most commonly employed in Canada and this is the second most commonly employed standard regimen 16 
.
Prognostic criteria determined by RPA of 1200 patients in RTOG trials 7 . RPA showed that poor prognostic features also included active extracranial metastases and an uncontrolled primary tumor. Gerrard et al, 17 performed three studies between 1997 and 2001. They revealed that three poor prognostic features, such as KPS < 70, over 60 years of age and primary other than breast cancer. All these prognostic factors were demonstrated in our study and by other authors 8, 11 . Patients with poor performance status and progressive extracranial disease, treatment interventions may fail to achieve benefits and associated with side effects 18 . Our data demonstrate that the use of RPA class may identify patients most likely to benefit from WBRT.
The role of chemotherapy in BM is controversial. Most of trials found no survival advantage with chemotherapy 19, 20, 21 . We found chemotherapy improved the median survival like Shenglin 22 who found that gefitinib improved the median survival and quality of life in non small lung cancer. Nicolas and colleagues 23 also found chemotherapy improved the median survival in non small lung cancer. A number of studies 24, 25 have, however, demonstrated favorable response rates and survival benefit in breast patients with BM receiving combination chemotherapy. This needs further investigations to demonstrate the value of chemotherapy. 
concLuSIon
WBRT is an effective treatment in the management of BM. Despite the use of WBRT, outcomes are still poor and more efforts should be made to incorporate multimodality treatments including surgery, radiosurgery, chemotherapy and radiotherapy sensitizers to improve survival. Patients with RPA class I may be effectively treated with local resection or radiosurgery followed by WBRT, mainly in those patients with single metastases, higher KPS and controlled extra cranial disease.
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